menu
    • menu
    [{"orgOrder":0,"company":"EmeraMed","sponsor":"NBMI Science AB","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Emeramide","moa":"Mercury | Iron","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"EmeraMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EmeraMed \/ NBMI Science AB","highestDevelopmentStatusID":"8","companyTruncated":"EmeraMed \/ NBMI Science AB"},{"orgOrder":0,"company":"EmeraMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Emeramide","moa":"Mercury | Iron","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EmeraMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EmeraMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EmeraMed \/ Undisclosed"},{"orgOrder":0,"company":"EmeraMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Emeramide","moa":"Mercury | Iron","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"EmeraMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EmeraMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EmeraMed \/ Undisclosed"},{"orgOrder":0,"company":"EmeraMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"NBMI","moa":"Mercury ion","graph1":"Neurology","graph2":"Phase II","graph3":"EmeraMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EmeraMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EmeraMed \/ Undisclosed"},{"orgOrder":0,"company":"EmeraMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"N1, N3-bis(2- mercaptoethyl)isophthalamide","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II\/ Phase III","graph3":"EmeraMed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EmeraMed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"EmeraMed \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by EmeraMed

    Menu

    EmeraMed

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EmeraMed

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EmeraMed

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NBMI

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)

                            Details : NBMI is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Supranuclear Palsy, Progressive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 03, 2019

                            Lead Product(s) : NBMI

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EmeraMed

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EmeraMed

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : N1, N3-bis(2- mercaptoethyl)isophthalamide

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NBMI Treatment in Patients With Mercury Toxicity

                            Details : N1, N3-bis(2- mercaptoethyl)isophthalamide is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Mercury Poisoning.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 03, 2019

                            Lead Product(s) : N1, N3-bis(2- mercaptoethyl)isophthalamide

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EmeraMed

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EmeraMed

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emeramide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation

                            Details : Emeramide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of beta-Thalassemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 17, 2019

                            Lead Product(s) : Emeramide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            EmeraMed

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EmeraMed

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emeramide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NBMI - Clinical Study on COPD

                            Details : Emeramide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 21, 2017

                            Lead Product(s) : Emeramide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            EmeraMed

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EmeraMed

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emeramide

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : NBMI Science AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication

                            Details : Emeramide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mercury Poisoning.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 01, 2015

                            Lead Product(s) : Emeramide

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : NBMI Science AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth